medigraphic.com
ISSN 1561-3127 (Electronic)
ISSN 0864-3466 (Print)

2022, Number 3

<< Back Next >>

Revista Cubana de Salud Pública 2022; 48 (3)

Impact and effectiveness of Abdala vaccine in Matanzas province in the face of symptomatic disease and death from COVID-19

Almenares RK, Más BP, Sánchez VL, Vidal LM, Dickinson MFO

Language: Spanish
References: 26
Page: 1-18
PDF size: 870.68 Kb.


ABSTRACT

Introduction: To obtain control of the COVID-19 epidemic in Cuba, the decision was made by the highest management of the government and the Ministry of Public Health to carry out a health intervention with Abdala vaccine in Matanzas province, due to its high incidence and mortality.
Objective: To estimate the impact and effectiveness of Abdala vaccine in the face of symptomatic disease of reported cases and death in hospitals in Matanzas province.
Methods: A retrospective cohort study was conducted, with a cohort of vaccinated people consisting of 252,557 people who met the three-dose schedule, and another of unvaccinated or who had not complied with the complete vaccination schedule of 325,462 people. Age and personal pathological history were explored. As a source of information, the registry of confirmed cases and deaths issued by the Ministry of Public Health and the automated vaccination base Andariego Higia were used. It was calculated the effectiveness (VE=1-RR) and by confidence intervals and analyzed epidemiological indicators with the Bayesian structural time series method. Results: The effectiveness against symptomatic disease and death was 75.5 % and 95.7 %, respectively. In the analysis of the causal impact, values of reduction of 90.0% of the reported incidence and 86.0% of mortality were evidenced with respect to the expected figures.
Conclusions: Abdala vaccine showed high effectiveness and impact in the prevention of symptomatic disease and death in real-world conditions.


REFERENCES

  1. Ritchie H, Mathieu E, Rodés-Guirao L, Appel C, Giattino Ch, Ortiz-Ospina E, et al -"Coronavirus Pandemic (COVID-19)". OurWorldInData.org.; 2020 [acceso 12/01/2022]Disponible en: 'https://ourworldindata.org/coronavirus'acceso

  2. WHO, Pan American Health Organization, European Commission. Cuban experiencewith local production of medicines, technology transfer and improving access to health.Geneva: World Health Organization; 2015 [acceso 20/11/2021]. Disponible en:https://apps.who.int/iris/handle/10665/336685

  3. CECMED. Aprueba el CECMED el Autorizo de Uso de Emergencia del candidatovacunal cubano ABDALA. La Habana: CECMED; 2021 [acceso 25/12/2021] Disponibleen: https://www.cecmed.cu/noticias/aprueba-cecmed-autorizo-uso-emergenciacandidato-vacunal-cubano-Abdala

  4. WHO. Evaluation of COVID-19 vaccine effectiveness Geneva: WHO; 2021 [acceso08/11/2021]. Disponible en: https://www.who.int/publications/i/item/WHO-2019-nCoVvaccine_effectiveness-measurement-2021.1

  5. Higia Andariego. Intervención Sanitaria. La Habana: MINSAP; 17 de mayo 2021[acceso 12/09/2021]. Disponible en: http://www.intervención.sld.cu

  6. Pelegrino-Martínez-de-la-Cotera J, Rodríguez-Lay L, Guzmán-Tirado M. Evaluaciónde la prueba inmunocromatográfica Sars-CoV-2 Rapid antigen test para detectarantígenos de Sars-CoV-2. Rev Cubana Med Trop . 2021 [acceso el 14/02/2022];73(2).Disponible en: http://revmedtropical.sld.cu/index.php/medtropical/article/view/682

  7. Brodersen KH, Gallusser F, Koehler J, Remy N, Scott SL. "Inferring causal impactusing Bayesian structural time-series models." Ann. Appl. Stat. 2015;9(1)247-74. DOI:10.1214/14-AOAS788

  8. Pomeranz D. Métodos de evaluación. Boston: Harvard Busines School; 2011 [acceso25/12/2021]. Disponible en:https://www.hbs.edu/ris/Supplemental%2520Files/Metodos-de-Evaluacion-deimpacto_50067.pdf

  9. Callaway E, Mallapaty S. Novavax COVID vaccine protects people against variants.But the experimental shot saw a worrying drop in efficacy against a lineage detected inSouth Africa. Nature. 2021 [acceso 08/01/2022];590(4):17. Disponible en:https://media.nature.com/original/magazine-assets/d41586-021-00268-9/d41586-021-00268-9.pdf

  10. Novavax Inc. Novavax COVID-19 vaccine demonstrates 89.3% efficacy in UK phase3 trial. Irlanda: Novavax Inc.; 2021 [acceso 12/01/2022] Disponible en:https://ir.novavax.com/news-releases/news-releasedetails/novavax-covid-19-vaccinedemonstrates-893- efficacy-uk-phase-3

  11. Shinde V, Bhikha S, Hoosain Z, Achary M, Bhorat Q, Fairlie L, et al. Efficacy ofNVXCoV2373 covid-19 vaccine against the B.1.351 variant. N Engl J Med. 2021[acceso

  12. 12/01/2022];384(20):1899-1909 Disponible en:https://www.nejm.org/doi/full/10.1056/NEJMoa210305512. Li XN, Huang Y, Wang W, Jing QL, Zhang CH, Qin PZ, et al. Effectiveness ofinactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: atest-negative case-control real-world study. Emerg Microbes Infect. 2021 [acceso08/01/2022];10(1):1751-9. Disponibleen: https://pubmed.ncbi.nlm.nih.gov/34396940/

  13. Chodick G, Tene L, Patalon T, Gazit S, Tov AB, Cohen D, et al. The effectiveness ofthe first dose of BNT162b2 vaccine in reducing SARS-CoV-2 infection 13-24 days afterimmunization: real-world evidence. medRxiv. 2021:2021.01.27.21250612. [Preprint][acceso 08/01/2022]. DOI: 10.1101/2021.01.27.21250612

  14. Hunter PR, Brainard J. Estimating the effectiveness of the Pfizer COVID-19BNT162b2 vaccine after a single dose. A reanalysis of a study of ‘real-world’ vaccinationoutcomes from Israel. medRxiv. 2021:2021.02.01.21250957. [Preprint] DOI:10.1101/2021.02.01.21250957

  15. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safetyand Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. New England Journal ofMedicine. 2020;383(27):2603-15. DOI: 10.1056/NEJMoa2034577

  16. Hyams C, Marlow R, Maseko Z, King J, Ward L, Fox K, et al. Effectiveness ofBNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventinghospitalisations in people aged at least 80 years: a test-negative, case-control study.LancetInfectDis. 2021;21(11):1539-48. DOI: 10.1016%2FS1473-3099(21)00330-3

  17. Chung H, He S, Nasreen S, Sundaram ME, Buchan SA, Wilson SE et al. CanadianImmunization Research Network (CIRN) Provincial Collaborative Network (PCN)Investigators. Effectiveness of BNT162b2 and mRNA-1273 covid19 vaccines againstsymptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada:test negative design study. BMJ. 2021 [acceso 11/09/2021];374:n1943. Disponible en:https://www.bmj.com/content/374/bmj.n1943

  18. Hungerford D, Cunliffe NA. Real world effectiveness of covid-19 vaccines. BMJ.2021;374:2034. DOI:10.1136/bmj.n2034

  19. Thompson M, Burgess J, Naleway A, Tyner H, Yoon S, Meece J, et al. InterimEstimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccinesin Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders,and Other Essential and Frontline Workers-Eight U.S. Locations, December 2020–March

  20. 2021. MMWR. 2021;70(13):495-500. DOI:10.15585/mmwr.mm7013e320. Jara A, Undurraga EA, González C, Paredes F, Fontecilla T, Jara G, et al.Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile. New England Journal ofMedicine. 2021;385(10):875-84. DOI: 10.1056/NEJMoa2107715

  21. González S, Santiago O, Calabria A, Salazar M, Marín L, Vázquez E, et al. CV.Informe: Efectividad de la primera dosis de la vacuna ChAdOx1 nCoV-19(Oxford/AstraZeneca-AZ) en la población de mayores entre 60 y 79 años. Buenos Aires: Ministerio de Salud de la Provincia de Buenos Aires; 2021 [acceso 12/12/2021].Disponible en: https://academianacionaldemedicina.org/publicaciones/covid-19/

  22. Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, Hernán MA, et al.BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. TheNew England Journal of Medicine. N Engl J Med.2021[acceso 22/12/2021];384;1412-

  23. Disponible en: https://www.nejm.org/doi/full/10.1056/NEJMc210428123. Chodick G, Tene L, Patalon T, Gazit S, Ben Tov A, Cohen D, et al. Assessment ofEffectiveness of 1 Dose of BNT162b2 Vaccine for SARS-CoV-2 Infection 13 to 24 DaysAfter Immunization. JAMA Netw Open. 2021 [acceso 22/12/2021];4(6):e2115985.Disponible en: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2780700

  24. Lavista JM, Richardson BA, Weeks WB. Association of COVID-19 vaccinationprioritization and hospitalization among older Washingtonians. J Am Geriatr Soc. 2021[acceso 12/01/2021];69(10):2780-2. Disponible en:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8242668/

  25. Mourtgos SM, Adams IT. COVID-19 vaccine program eliminates law enforcementworkforce infections: a Bayesian structural time series analysis, Police Practice andResearch. 2021;22(5):1557-65. DOI: 10.1080/15614263.2021.1894937

  26. Toharudin T, Pontoh RS, Caraka RE, Zahroh S, Kendogo P, Sijabat N, et al. NationalVaccination and Local Intervention Impacts on COVID-19. Cases. Sustainability.2021;13:8282. DOI: 10.3390/su13158282




2020     |     www.medigraphic.com